Stockholders v Immucor, Inc.
Stockholders File Lawsuit Against Immucor, Inc.
According to a press release dated August 27, 2009, the complaint charges Immucor and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Immucor develops, manufactures and sells a complete line of reagents and automated systems used primarily by hospitals, clinical laboratories and blood banks in a number of tests performed to detect and identify certain properties of the cell and serum components of human blood prior to blood transfusion.
The complaint alleges that during the Class Period, defendants materially misrepresented the Companys business operations. Specifically, defendants failed to disclose that Immucor was operating in violation of the federal antitrust laws of the United States.
The complaint further alleges that on April 24, 2009, the Company issued a press release, which stated in part: Immucor, Inc., a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that it received a subpoena from the United States Department of Justice, Antitrust Division, requesting documents for the period beginning September 1, 2000 through the present, pertaining to an investigation of possible violations of the federal criminal antitrust laws in the blood reagents industry. Immucor intends to fully cooperate with the investigation.
If you bought Immucor, Inc. securities and would like to obtain information about the Immucor, Inc. lawsuit, then you are invited to call Kahn Swick & Foti, LLC toll free at (866) 467-1400 extension 100 to speak with an attorney or visit www.ksfcounsel.com.
